Head and Neck Cancer

P53 suppressor gene studied

Published in Cancer Weekly, November 5th, 2002

Montefiore Medical Center researchers are studying a new drug that has the potential to fight recurrent and highly resistant head and neck cancer. Montefiore is the only medical center in New York City involved in the phase III, multi-institutional national study that will enroll 140 people.

"The drug is designed to kill the cancer cells and to stop tumor growth by using what is called the p53 suppressor gene," said Missak Haigentz, MD, an oncologist and principal investigator for the study at Montefiore. The p53 gene, when mutated, is frequently associated with the unregulated growth of cancer cells.

Head and neck cancers account for approximately...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-11-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry